Breaking News
9 hours ago
Vaibhavi M.
Medix Biochemica appoints Petra Furu as CEO to lead growth strategy, strengthen IVD business operations, and drive expansion across global diagnostics markets.
Vaibhavi M.
Dogwood Therapeutics secures FDA IND approval for SP16 to treat chemotherapy-induced peripheral neuropathy, enabling Phase 1b trial initiation in 2026.
Vaibhavi M.
Achieve Life Sciences advances cytisinicline manufacturing with Adare and targets NDA resubmission in 2026 for nicotine dependence treatment following FDA review timeline.
Vaibhavi M.
Plus Therapeutics appoints Randy Goodman as VP HEOR to lead value strategy, pricing, and market access for CNSide and REYOBIQ in its CNS oncology pipeline development.
Vaibhavi M.